Biogen rises as investors react to fresh kidney-disease data and pipeline optimism

Biogen (BIIB) is up 4.6% today. Here is some analysis on what might have caused this price movement. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-nephrology-portfolio-including))

Analysis: The most likely driver is renewed enthusiasm around Biogen’s nephrology franchise after the company outlined new long-term EMPAVELI data and additional kidney-disease presentations for this week’s major nephrology meeting. The move may also reflect continuing optimism that Biogen’s Apellis deal and broader late-stage pipeline can strengthen growth beginning in 2027, with earnings due on October 28, 2026. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-nephrology-portfolio-including))

Details:

Biogen said on October 19 that it will present 76-week EMPAVELI results showing sustained proteinuria reduction, continued eGFR stabilization, and a consistent long-term safety profile in C3G and primary IC-MPGN. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-nephrology-portfolio-including))

The same update also highlighted felzartamab and other nephrology programs, giving investors another reminder that kidney disease is becoming a larger strategic focus for the company. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-nephrology-portfolio-including))

Biogen’s Apellis acquisition materials describe EMPAVELI and SYFOVRE as growth products and say the transaction is expected to become increasingly accretive to non-GAAP EPS starting in 2027. ([investors.biogen.com](https://investors.biogen.com/static-files/8d26129a-12f2-42be-98c4-1f0e4fcc5e84))

Biogen has scheduled its third-quarter 2026 earnings webcast for October 28, which may be adding event-driven interest alongside the pipeline news. ([investors.biogen.com](https://investors.biogen.com/events/event-details/q3-2026-earnings-call-webcast))

Sources:

Biogen, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIIB Insider Trading Activity

$BIIB insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:

LLOYD MINOR has made 0 purchases and 2 sales selling 1,186 shares for an estimated $239,749.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BIIB Hedge Fund Activity

We have seen 520 institutional investors add shares of $BIIB stock to their portfolio, and 380 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 5,409,698 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $1,168,819,349
JPMORGAN CHASE & CO added 1,823,140 shares (+inf%) to their portfolio in Q2 2026, for an estimated $393,907,628
PACER ADVISORS, INC. added 1,122,981 shares (+inf%) to their portfolio in Q2 2026, for an estimated $242,631,274
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,117,663 shares (+inf%) to their portfolio in Q2 2026, for an estimated $241,482,267
VAN ECK ASSOCIATES CORP removed 981,752 shares (-90.9%) from their portfolio in Q2 2026, for an estimated $212,117,337
POINT72 ASSET MANAGEMENT, L.P. removed 721,468 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $155,880,376
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 664,588 shares (-85.4%) from their portfolio in Q2 2026, for an estimated $143,590,883

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BIIB Congressional Stock Trading

Members of Congress have traded $BIIB stock 7 times in the past 6 months. Of those trades, 4 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 5 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 2 sales worth up to $65,000 on 09/24, 06/02.
REPRESENTATIVE KEVIN HERN sold up to $15,000 on 08/18.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/05.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BIIB Analyst Ratings

Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 06/29/2026
Evercore ISI Group issued a "Outperform" rating on 05/15/2026
Guggenheim issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $BIIB, check out Quiver Quantitative's $BIIB forecast page.

$BIIB Price Targets

Multiple analysts have issued price targets for $BIIB recently. We have seen 8 analysts offer price targets for $BIIB in the last 6 months, with a median target of $223.5.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $222.0 on 07/08/2026
Brian Abrahams from RBC Capital set a target price of $242.0 on 07/07/2026
Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
Laura Chico from Wedbush set a target price of $196.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.